LCM
ABVX

Legato Capital Management’s Abivax ABVX Stock Holding History

Legato Capital Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,533
Closed -$1.17M – 679
2026
Q1 		$1.17M Sell
10,533
-115
-1% -$13.6K 0.11% 246
2025
Q4 		$1.44M Buy
10,648
+8,094
+317% +$883K 0.12% 260
2025
Q3 		$217K Buy
+2,554
New +$157K 0.02% 509

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legato Capital Management's ABVX Position: Q2 2026 in Review

Legato Capital Management sold out of Abivax (ABVX) in Q2 2026, closing a stake of 10,533 shares — an estimated $1.17M sold.

Legato Capital Management first reported a position in ABVX in Q3 2025 and held it in 3 quarters. The position peaked at $1.44M in Q4 2025. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Legato Capital Management reported no remaining Abivax position as of Q2 2026 after selling out during the quarter.
  • Legato Capital Management sold 10,533 Abivax shares in Q2 2026, an estimated $1.17M.
  • Legato Capital Management first reported a position in Abivax in Q3 2025 and held it in 3 quarters.
  • Legato Capital Management's Abivax position peaked at $1.44M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.